Payment overview · 2025
General Payments
$1,071.90
34 reported records · 12 companies
Healthcare provider profile · identity verified
Vijay Kumar Sharma, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1922169028
Verified facts
What the public records show
CMS Open Payments records show Vijay Kumar Sharma, M.D. received $1,071.90 in general payments during 2025 across 34 reported records.
Corcept Therapeutics accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $209.19 | 19.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $193.91 | 18.1% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $166.26 | 15.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.01 | 14.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $140.44 | 13.1% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $51.85 | 4.8% | 3 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $42.95 | 4.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.18 | 3.8% | 2 | 2025 |
| BioMarin Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $26.95 | 2.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.05 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.71 | 2.0% | 1 | 2025 |
| LifeNet Health | Unresolved — no canonical attribution shown | $6.40 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,071.90 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $209.19 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $175.83 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $175.83 | 13 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $166.26 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.01 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $140.44 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| VOXZOGO 1.2mg Normalized: voxzogo 1 2mg |
Drug | BioMarin Pharmaceutical Inc. | $26.95 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| TheraGenesis Wound Matrix Normalized: theragenesis wound matrix |
Device | LifeNet Health | $6.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 94 |
| Eliquis | Apixaban | 169 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 47 |
| Gabapentin | Gabapentin | 160 | 72 |
| Losartan Potassium | Losartan Potassium | 146 | 66 |
| Nifedipine Er | Nifedipine | 137 | 46 |
| Tramadol Hcl | Tramadol Hcl | 131 | 44 |
| Lisinopril | Lisinopril | 124 | 44 |
| Furosemide | Furosemide | 123 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 38 |
| Carvedilol | Carvedilol | 118 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 61 |
| Famotidine | Famotidine | 103 | 44 |
| Omeprazole | Omeprazole | 100 | 43 |
| Potassium Chloride | Potassium Chloride | 96 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 34 |
| Trazodone Hcl | Trazodone Hcl | 84 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 32 |
| Sertraline Hcl | Sertraline Hcl | 78 | 20 |
| Levetiracetam | Levetiracetam | 75 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 24 |
| Metformin Hcl | Metformin Hcl | 71 | 31 |
| Jardiance | Empagliflozin | 69 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 17 |
| Donepezil Hcl | Donepezil Hcl | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 26 |
| Montelukast Sodium | Montelukast Sodium | 56 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 22 |
| Ibuprofen | Ibuprofen | 52 | 18 |
| Mirtazapine | Mirtazapine | 52 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 16 |
| Alendronate Sodium | Alendronate Sodium | 51 | 13 |
| Baclofen | Baclofen | 51 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 50 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 15 |
| Entresto | Sacubitril/Valsartan | 37 | 19 |
| Allopurinol | Allopurinol | 36 | 17 |
| Santyl | Collagenase Clostridium Hist. | 36 | 13 |
| Spironolactone | Spironolactone | 35 | 15 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Latanoprost | Latanoprost | 33 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 14 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | 11 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 14 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | 15 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Lactulose | Lactulose | 19 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | 11 |
| Trulicity | Dulaglutide | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | 11 |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,071.90 · 34 records | Corcept Therapeutics | CAMZYOS, COLLAGENASE SANTYL, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, KRYSTEXXA, Kerendia, Korlym, OTEZLA, Ozempic, REPATHA, TheraGenesis Wound Matrix, VENASEAL, VOXZOGO 1.2mg | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error